logo
  

Fudgeamentals Recalls Chocolate Fudge Bites

chocolatefudgebites nove18 lt

Melville, New York-based Fudgeamentals has recalled one lot of Chocolate Fudge Bites packaged in 8 oz. plastic containers citing undeclared walnuts, the U.S. Food and Drug Administration said.

The Chocolate Fudge Bites products may contain Chocolate Walnut Fudge Bites products instead, resulting in the presence of undeclared tree nut (walnut) ingredient.

The affected product comes in a clear plastic container labeled Chocolate Fudge Bites, marked with lot #22301015 and UPC code 840235800392. They were distributed through Fareway retail stores in Iowa, Illinois, Minnesota, Nebraska, and South Dakota.

The recall was initiated after one of the store employees discovered Chocolate Walnut Fudge Bites were incorrectly labeled as Chocolate Fudge Bites.

Consumers who have an allergy or severe sensitivity to tree nuts (walnuts) may get serious or life-threatening allergic reactions if they consume these products and are urged not to consume this item.

However, no illnesses have been reported to date in connection with the recalled product.

Consumers are urged to discard the product or return it to the place of purchase for a full refund.

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT